NasdaqCM:RAVE
NasdaqCM:RAVEHospitality

US Penny Stocks To Consider In February 2025

As the U.S. stock market faces a challenging period, with major indices like the Dow Jones Industrial Average on track for significant weekly declines, investors are increasingly looking for opportunities that might buck broader trends. The term "penny stocks" may seem outdated, but these smaller or newer companies can still offer intriguing possibilities when they exhibit strong financial health. In this article, we'll explore several penny stocks that stand out due to their financial...
NasdaqGS:RARE
NasdaqGS:RAREBiotechs

Exploring Three High Growth Tech Stocks in the United States

In the last week, the United States market has been flat, yet it has shown a robust 21% increase over the past year, with earnings expected to grow by 14% annually in the coming years. In this context of overall market growth and stability, identifying high growth tech stocks involves looking for companies with strong innovation potential and solid financial health that can capitalize on these favorable conditions.
NYSE:GMED
NYSE:GMEDMedical Equipment

Globus Medical (NYSE:GMED) Reports Strong Sales Growth But Sees US$20 Million Dip In Annual Net Income

Globus Medical (NYSE:GMED) recently reported mixed financial results, with a significant rise in sales to USD 2,519 million but a drop in net income to USD 103 million for the full year ending December 2024. The company's share price exhibited a minor shift of 0.01% in the past week, occurring amidst broader market fluctuations that saw major indexes like the Dow Jones and Nasdaq experience declines due to factors including the UnitedHealth DOJ probe and tech stock performance. While Globus...
NasdaqGS:HOLX
NasdaqGS:HOLXMedical Equipment

Hologic (NasdaqGS:HOLX) Expands Global Reach With CE-Marked Affirm Contrast Biopsy Software

Hologic (NasdaqGS:HOLX) recently announced the CE-marking of its Affirm Contrast Biopsy Software, enhancing its breast imaging portfolio with advanced diagnostic capabilities. Concurrently, the company's Aptima SARS-CoV-2 assay gained 510(k) FDA clearance, solidifying its commitment to respiratory diagnostics. Over the last week, Hologic's share price saw a modest increase of 1.1%. This price movement occurred amidst a backdrop of downward pressures in major markets, with the Dow Jones, S&P...